P
Patrizia Mondello
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 95
Citations - 1720
Patrizia Mondello is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Diffuse large B-cell lymphoma. The author has an hindex of 23, co-authored 75 publications receiving 1344 citations. Previous affiliations of Patrizia Mondello include University of Lugano & Cornell University.
Papers
More filters
Journal ArticleDOI
Vascular access for hemodialysis: current perspectives.
Domenico Santoro,Filippo Benedetto,Patrizia Mondello,Narayana Pipitò,David Barillà,Francesco Spinelli,CarloAlberto Ricciardi,Cernaro,Michele Buemi +8 more
TL;DR: A well-functioning vascular access (VA) is a mainstay to perform an efficient hemodialysis (HD) procedure and has the lowest association with morbidity and mortality, and for this reason AVF use is strongly recommended by guidelines from different countries.
Journal ArticleDOI
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Elliott J. Brea,Elliott J. Brea,Claire Y. Oh,Claire Y. Oh,Eusebio Manchado,Sadna Budhu,Ron S. Gejman,Ron S. Gejman,George Mo,Patrizia Mondello,James E. Han,James E. Han,Casey A. Jarvis,David Ulmert,Qing Xiang,Aaron Y Chang,Aaron Y Chang,Ralph Garippa,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Neal Rosen,Neal Rosen,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe,David A. Scheinberg,David A. Scheinberg +27 more
TL;DR: Kinome screens revealed EGFR and MEK as key to reduced MHCI expression on many tumors, providing a rationale for clinically testing similar kinase inhibitors with immunotherapies dependent on MHC-I.
Journal ArticleDOI
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Patrizia Mondello,Saber Tadros,Matt Teater,Lorena Fontan,Aaron Y. Chang,Neeraj Jain,Huan Yang,Shailbala Singh,Hsia-Yuan Ying,Chi-Shuen Chu,Man Chun John Ma,Eneda Toska,Stefan Alig,Matthew Durant,E. De Stanchina,Sreejoyee Ghosh,Anja Mottok,Loretta J. Nastoupil,Sattva S. Neelapu,Oliver Weigert,Giorgio Inghirami,Jose Baselga Baselga,Anas Younes,Cassian Yee,Ahmet Dogan,David A. Scheinberg,Robert G. Roeder,Ari Melnick,Michael R. Green +28 more
TL;DR: HAC3 inhibition represents a novel mechanism-based immune-epigenetic therapy for CREBBP mutant lymphomas and restored the ability of tumor infiltrating lymphocytes to kill DLBCL cells in an MHC class I and II dependent manner.
Journal ArticleDOI
Pim kinases in hematological malignancies: where are we now and where are we going?
TL;DR: An overview of the biological activity of PIM-kinases, their role in hematologic malignancies and future therapeutic opportunities is provided.
Journal ArticleDOI
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.
Massimo Offidani,L Corvatta,Laura Maracci,Anna Marina Liberati,Stelvio Ballanti,Immacolata Attolico,Patrizia Caraffa,Francesco Alesiani,T. Caravita di Toritto,S Gentili,Patrizia Tosi,Marino Brunori,Daniele Derudas,Antonio Ledda,Alessandro Gozzetti,Claudia Cellini,Lara Malerba,Anna Mele,Alessandro Andriani,Sara Galimberti,Patrizia Mondello,Stefano Pulini,U Coppetelli,Paolo Fraticelli,Attilio Olivieri,P. Leoni +25 more
TL;DR: The BVD regimen is feasible, effective and well-tolerated in difficult-to-treat patients with rrMM.